Rx Surveillance User Fee Proposal Is Premature; PhRMA Responds To JAMA
Executive Summary
Discussion of ways to fund expanded post-marketing surveillance activities by FDA should await a clear assessment of the extent of the problem, the Pharmaceutical Research & Manufacturers of America said in response to a May 20 Journal of the American Medical Association article entitled "Time To Take Action on Drug Safety."
You may also be interested in...
Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer
The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers
Senate Vioxx Hearing Looks Like Tough Going For Merck, Pfizer
The first Congressional hearing into the withdrawal of Vioxx is likely to put both Merck and FDA on the defensive for their handling of safety data - and could revive similar allegations about Pfizer involving calcium channel blockers
FDA Risk Cmte. Includes “Cooperative Agreement” Grantee Gardner
FDA Drug Safety & Risk Management Subcommittee member Jacqueline Gardner, PhD, is a former grantee of the agency's cooperative agreement program to provide active surveillance data for the Office of Drug Safety